Statistics found here the category is Drug-related infectious diseases (INF)

Category	Title
INF	INF-1. AIDS incidence by year of diagnosis among injecting drug users by country, cases per million 1998 to 2009 - EU countries, Croatia, Turkey and Norway
INF	INF-2. HIV infections newly diagnosed in injecting drug users, cases per million by country and year of diagnosis 1998–2009. Part (i) EU countries, Croatia, Turkey and Norway: five highest countries in peak value 2004-2009
INF	INF-2. HIV infections newly diagnosed in injecting drug users, cases per million by country and year of diagnosis 1998–2009. Part (ii) EU countries, Croatia, Turkey and Norway: countries with 5 to 10 cases per million population in peak value 2004-2009
INF	INF-3. HIV prevalence among injecting drug users — studies with national and subnational coverage Part (i) All injecting drug users, 2008 to 2009
INF	INF-3. HIV prevalence among injecting drug users — studies with national and subnational coverage Part (ii) Young injecting drug users (under age 25), 2008 to 2009
INF	INF-3. HIV prevalence among injecting drug users — studies with national and subnational coverage Part (iii) New injecting drug users (injecting less than 2 years), 2008 to 2009
INF	INF-6. HCV antibody prevalence among injecting drug users — studies with national and subnational coverage Part (i) All injecting drug users, 2008 to 2009
INF	INF-6. HCV antibody prevalence among injecting drug users — studies with national and subnational coverage Part (ii) Young injecting drug users (under age 25), 2008 to 2009
INF	INF-6. HCV antibody prevalence among injecting drug users — studies with national and subnational coverage Part (iii) New injecting drug users (injecting less than 2 years), 2008 to 2009
INF	INF-9. Prevalence of markers of HBV infection estimated among injecting drug users — studies with national and subnational coverage Part (i) Percentage ever infected (positive for aHBc), 2008 to 2009
INF	INF-9. Prevalence of markers of HBV infection among injecting drug users - studies with national and subnational coverage Part (ii) Percentage with current infection (positive for HBsAg), 2008 to 2009
INF	INF-0. Bibliographic references
INF	INF-1. Prevalence of HIV infection among injecting drug users in the EU countries, Croatia, Turkey and Norway, 2009 or most recent year available — Summary table by country
INF	INF-2. Prevalence of HCV antibody among injecting drug users in the EU countries, Croatia, Turkey and Norway, 2009 or most recent year available — Summary table by country
INF	INF-3. Prevalence of markers for HBV infection among injecting drug users in the EU countries, Croatia, Turkey and Norway, 2009 or most recent year available — Summary table by country
INF	INF-104. HIV infections newly diagnosed and AIDS diagnosed among injecting drug users, by country and year of diagnosis Part (i) HIV infection in the EU countries, Croatia, Turkey and Norway: (a) cases per million population, (b) number of cases and (c) population sizes
INF	INF-104. HIV infections newly diagnosed and AIDS diagnosed among injecting drug users, by country and year of diagnosis Part (ii) AIDS incidence in the EU countries, Croatia, Turkey and Norway: (a) cases per million population, (b) number of cases and (c) population sizes
INF	INF-105. Notified cases of hepatitis C infection among injecting drug users in the EU countries, Croatia and Norway: a) Total number of cases where transmission route known, b) number of IDU cases, and c) percentage of IDUs amongst all cases with known risk factor
INF	INF-106. Notified cases of hepatitis B infection among injecting drug users in the EU countries, Croatia and Norway: a) Total number of cases where transmission route known, b) number of IDU cases, and c) percentage of IDUs amongst all cases with known risk factor
INF	INF-107. Incidence studies of hepatitis C virus infection among injecting drug users in the EU countries
INF	INF-108. Prevalence of HIV infection among injecting drug users (%), 1991 to 2009. EU countries, Croatia, Turkey and Norway
INF	INF-109. Prevalence of HIV infection among injecting drug users under age 25 (%), 1991 to 2009. EU countries, Croatia, Turkey and Norway
INF	INF-110. Prevalence of HIV infection among new (injecting less than 2 years) injecting drug users (%), 1991 to 2009. EU countries, Croatia, Turkey and Norway
INF	INF-111. Prevalence of hepatitis C infection among injecting drug users (%), 1991 to 2009. EU countries, Croatia, Turkey and Norway
INF	INF-112. Prevalence of hepatitis C infection among injecting drug users under age 25 (%), 1991 to 2009. EU countries, Croatia, Turkey and Norway
INF	INF-113. Prevalence of hepatitis C infection among new (injecting less than 2 years) injecting drug users (%), 1991 to 2009. EU countries, Croatia, Turkey and Norway
INF	INF-114. Prevalence of current hepatitis B infection among injecting drug users (% with HBsAg), 1991 to 2009. EU countries, Croatia, Turkey and Norway
INF	INF-115. Prevalence of antibodies against hepatitis B virus among injecting drug users (%), 1991 to 2009. EU countries, Croatia, Turkey and Norway
INF	INF-117. Prevalence of HIV, HCV and HBV among drug users in prison, 1991 to 2009 Part (i) Prevalence of HIV infection (percentage) among injecting drug users in Prison
INF	INF-117. Prevalence of HIV, HCV and HBV among drug users in prison, 1991 to 2009 Part(ii) Prevalence of hepatitis C infection (%) among injecting drug users in Prison
INF	INF-117. Prevalence of HIV, HCV and HBV among drug users in prison, 1991 to 2009 Part(iii) Prevalence of current hepatitis B infection (percentage with HBsAg) among injecting drug users in Prison
INF	INF-117. Prevalence of HIV, HCV and HBV among drug users in prison, 1991 to 2009 Part(iv) Prevalence of antibodies against hepatitis B virus (percentage) among injecting drug users in Prison